Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy

Basit Öğe Kaydı
dc.authoridCecen, Olida/0000-0001-7969-2481
dc.authoridUnay Demirel, Ozlem/0000-0002-3059-9398
dc.authoridUluisik, Isilsu Ezgi/0000-0002-4279-3489
dc.authoridfuruncuoglu, yavuz/0000-0002-6716-5577
dc.contributor.authorCosan, Fulya
dc.contributor.authorDemirel, Ozlem Unay
dc.contributor.authorYalcin, Demet
dc.contributor.authorSonkaya, Muhammed Mert
dc.contributor.authorUluisik, Isilsu Ezgi
dc.contributor.authorCecen, Olida
dc.contributor.authorFuruncuoglu, Yavuz
dc.date.accessioned2024-05-19T14:39:05Z
dc.date.available2024-05-19T14:39:05Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBackgroundThe importance of COVID-19 vaccination for patients on immunosuppressive (IS) medication has increased due to the high risk of severe disease or mortality. Different vaccines have varying efficacy rates against symptomatic COVID-19, ranging from 46.8% to 95%. The objective of this study was to examine the differences in anti-Spike IgG, anti-Spike IgA, and neutralizing antibody (NAb) activity between the inactive CoronaVac vaccine and the mRNA-based BNT162b2 vaccine in IS patients.MethodA total of 441 volunteers, including 104 IS patients, 263 healthy controls (HC), who received two doses of CoronaVac or BNT162b2, and 74 unvaccinated patients with a history of SARS-CoV-2 infection, were included in the study. Anti-spike IgG, IgA, and NAb activity were investigated.ResultsImmunogenicity with BNT162b2 was higher than with CoronaVac, but in IS groups, it was lower than HC (CoronaVac-IS: 79.3%, CoronaVac-HC: 96.5%, p < 0.001; BNT162b2-IS: 91.3%, BNT162b2-HC: 100%, p = 0.005). With CoronaVac, anti-Spike IgG levels were significantly lower than BNT162b2 (CoronaVac-IS: 234.5AU/mL, CoronaVac-HC: 457.85AU/mL; BNT162b2-IS: 5311.2AU/mL, BNT162b2-HC: 8842.8AU/mL). NAb activity in the BNT162b2 group was significantly higher. NAb and anti-Spike IgG levels were found to be correlated. Among the IS group, a significantly lower response to the vaccines was observed when using rituximab. IgA levels were found to be lower with CoronaVac.ConclusionsAlthough immunogenicity was lower in IS patients, an acceptable response was obtained with both vaccines, and significantly higher anti-Spike IgG, anti-Spike IgA, and NAb activity levels were obtained with BNT162b2.en_US
dc.identifier.doi10.1186/s41927-023-00342-x
dc.identifier.issn2520-1026
dc.identifier.issue1en_US
dc.identifier.pmid37468956en_US
dc.identifier.scopus2-s2.0-85165325717en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org10.1186/s41927-023-00342-x
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4697
dc.identifier.volume7en_US
dc.identifier.wosWOS:001029444800001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofBmc Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectAnti-Spike Iggen_US
dc.subjectAnti-Spike Igaen_US
dc.subjectBnt162b2en_US
dc.subjectCoronavacen_US
dc.subjectImmunosuppressiveen_US
dc.subjectNeutralizing Antibody Activityen_US
dc.titleComparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu